Baker Hughes & C3 AI Release BHC3 Production Schedule Optimization Application for Demand Planning & Manufacturing Production Scheduling
3.3.2021 17:00:00 EET | Business Wire | Press release
Baker Hughes (NYSE: BKR) and C3 AI (NYSE: AI) have announced the launch of BHC3™ Production Schedule Optimization (PSO), an enterprise AI application for industrial demand planning and manufacturing production scheduling. The application improves supply chain and delivery performance for highly engineered products while minimizing manufacturing costs by generating industrial customer demand predictions and optimal production schedules using a holistic view of buyer activity, supply chain materials, and manufacturing and distribution operations.
BHC3 PSO produces accurate demand forecasts for industrial and oil and gas operations as well as defined manufacturing and distribution schedules, factoring in dynamic market conditions, operational constraints, and the inherent uncertainty associated with these operations. BHC3 PSO also generates actionable insights for buyers, sellers, inventory analysts and production schedulers to make near real-time adjustments to production schedules for industrial and oil and gas operations. The application is now generally available to oil and gas and manufacturing businesses globally and is the latest addition to the growing portfolio of BHC3 artificial intelligence (AI) applications from the BakerHughesC3.ai alliance.
BHC3 PSO integrates a wide range of inputs, including feedstock availability, changing market prices, priority customer orders, increasing reworks, and unplanned downtime. With the application, users can optimize goals across manufacturing and distribution activities, including inventory minimization and throughput maximization, while considering operational constraints including storage policy, asset performance, and resource availability.
BHC3 PSO has already demonstrated success with trial customers. For example, a large hydrocarbon processing company that configured the BHC3 PSO application for a polypropylene plant was able to optimize production schedules and reduce manufacturing costs. After a 16-week trial, the company achieved a 20% improvement in demand forecasting accuracy by generating optimal production schedules without manual adjustment and adopting machine learning models.
“We are committed to leading and advancing the digital transformation of energy operations globally. This application is the latest in a series of new AI solutions we have launched in recent months that allow customers to achieve significant cost reductions, new levels of productivity, and organizational alignment for highly engineered products and industrial plants,” said Ed Abbo, C3 AI president and CTO. “BHC3 Production Schedule Optimization supports discrete, batch, semi-batch, and continuous manufacturing processes in network and multi-stage environments, delivering cost and productivity benefits across midstream and downstream oil, gas, and chemicals operations."
“Enterprise AI has the ability to create value and deliver results for manufacturing across the energy value chain,” said Uwem Ukpong, executive vice president of regions, alliances & enterprise sales at Baker Hughes. “Optimization of the supply chain and reduction of production costs are especially relevant today for energy and industrial businesses. BHC3 Production Schedule Optimization combines the manufacturing and technology expertise of Baker Hughes with C3 AI’s leading technology to help operators better forecast materials production to serve their customers.”
For more information about BHC3 product offerings, please visit BakerHughesC3.ai.
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of Enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About Baker Hughes
Baker Hughes (NYSE: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and with operations in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005570/en/
Contact information
C3.ai Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
Investor Relations
IR@C3.ai
Baker Hughes Contacts:
Media Relations
Ashley Nelson
+1 925-316-9197
Ashley.nelson1@bakerhughes.com
Investor Relations
Jud Bailey
+1 281-809-9088
investor.relations@bakerhughes.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom